-
公开(公告)号：US08501171B2
公开(公告)日：2013-08-06
申请号：US12659824
申请日：2010-03-23
申请人： Dominique Bourel , Sylvie Jorieux , Christophe De Romeuf , Philippe Klein , Christine Gaucher , Nicolas Bihoreau , Emmanuel Nony
发明人： Dominique Bourel , Sylvie Jorieux , Christophe De Romeuf , Philippe Klein , Christine Gaucher , Nicolas Bihoreau , Emmanuel Nony
IPC分类号： A61K39/395
CPC分类号： C07K16/34 , A61K2039/505 , C07K16/18 , C07K16/2833 , C07K2317/14 , C07K2317/41 , C07K2317/732 , Y02A50/412
摘要： The invention concerns the use of human or humanized chimeric monoclonal antibodies which are produced in selected cell lines, said antibodies bringing about a high ADCC activity as well as a high secretion of cytokines and interleukins, for treating underpopulations of so-called weak-response patients exhibiting CD16 FCGR3A-158F homozygote or FCGR3A-158V/F heterozygote polymorphism.
-
公开(公告)号：US07713524B2
公开(公告)日：2010-05-11
申请号：US10566358
申请日：2004-07-30
申请人： Dominique Bourel , Sylvie Jorieux , Christophe De Romeuf , Philippe Klein , Christine Gaucher , Nicolas Bihoreau , Emmanuel Nony
发明人： Dominique Bourel , Sylvie Jorieux , Christophe De Romeuf , Philippe Klein , Christine Gaucher , Nicolas Bihoreau , Emmanuel Nony
IPC分类号： A61K39/395 , C07K16/00
CPC分类号： C07K16/34 , A61K2039/505 , C07K16/18 , C07K16/2833 , C07K2317/14 , C07K2317/41 , C07K2317/732 , Y02A50/412
摘要： The invention concerns the use of human or humanized chimeric monoclonal antibodies which are produced in selected cell lines, said antibodies bringing about a high ADCC activity as well as a high secretion of cytokines and interleukins, for treating underpopulations of so-called weak-response patients exhibiting CD16 FCGR3A-158F homozygote or FCGR3A-158V/F heterozygote polymorphism.
摘要翻译： 本发明涉及在所选细胞系中产生的人或人源化嵌合单克隆抗体的用途，所述抗体导致高ADCC活性以及细胞因子和白细胞介素的高分泌，用于治疗所谓的弱反应患者的人群 显示CD16 FCGR3A-158F纯合子或FCGR3A-158V / F杂合子多态性。
-
公开(公告)号：US20060182741A1
公开(公告)日：2006-08-17
申请号：US10566358
申请日：2004-07-30
申请人： Dominique Bourel , Sylvie Jorieux , Christophe De Romeuf , Philippe Klein , Christine Gaucher , Nicolas Bihoreau , Emmanuel Nony
发明人： Dominique Bourel , Sylvie Jorieux , Christophe De Romeuf , Philippe Klein , Christine Gaucher , Nicolas Bihoreau , Emmanuel Nony
IPC分类号： A61K39/395 , C07K16/44
CPC分类号： C07K16/34 , A61K2039/505 , C07K16/18 , C07K16/2833 , C07K2317/14 , C07K2317/41 , C07K2317/732 , Y02A50/412
摘要： The invention concerns the use of human or humanized chimeric monoclonal antibodies which are produced in selected cell lines, said antibodies bringing about a high ADCC activity as well as a high secretion of cytokines and interleukins, for treating underpopulations of so-called weak-response patients exhibiting CD16 FCGR3A-158F homozygote or FCGR3A-158V/F heterozygote polymorphism.
摘要翻译： 本发明涉及在所选细胞系中产生的人或人源化嵌合单克隆抗体的用途，所述抗体导致高ADCC活性以及细胞因子和白细胞介素的高分泌，用于治疗所谓的弱反应患者的人群 显示CD16 FCGR3A-158F纯合子或FCGR3A-158V / F杂合子多态性。
-
公开(公告)号：US20100303826A1
公开(公告)日：2010-12-02
申请号：US12659824
申请日：2010-03-23
申请人： Dominique Bourel , Sylvie Jorieux , Christophe De Romeuf , Philippe Klein , Christine Gaucher , Nicolas Bihoreau , Emmanuel Nony
发明人： Dominique Bourel , Sylvie Jorieux , Christophe De Romeuf , Philippe Klein , Christine Gaucher , Nicolas Bihoreau , Emmanuel Nony
IPC分类号： A61K39/395 , A61K39/42 , A61P31/12 , A61P37/00
CPC分类号： C07K16/34 , A61K2039/505 , C07K16/18 , C07K16/2833 , C07K2317/14 , C07K2317/41 , C07K2317/732 , Y02A50/412
摘要： The invention concerns the use of human or humanized chimeric monoclonal antibodies which are produced in selected cell lines, said antibodies bringing about a high ADCC activity as well as a high secretion of cytokines and interleukins, for treating underpopulations of so-called weak-response patients exhibiting CD16 FCGR3A-158F homozygote or FCGR3A-158V/F heterozygote polymorphism.
摘要翻译： 本发明涉及在所选细胞系中产生的人或人源化嵌合单克隆抗体的用途，所述抗体导致高ADCC活性以及细胞因子和白细胞介素的高分泌，用于治疗所谓的弱反应患者的人群 显示CD16 FCGR3A-158F纯合子或FCGR3A-158V / F杂合子多态性。
-
5.发明申请Correlation between the fucose content/galactose content ratio of anti-rhesus-d and anti-hla-dr antibodies and the adcc activity 审中-公开抗恒河猴和抗hla-dr抗体的岩藻糖含量/半乳糖含量比与adcc活性的相关性公开(公告)号：US20070015239A1
公开(公告)日：2007-01-18
申请号：US10575333
申请日：2004-10-20
CPC分类号： C07K16/00 , A61K2039/505 , C07K16/2833 , C07K16/34 , C07K2317/21 , C07K2317/24 , C07K2317/41 , C07K2317/732
摘要： The present invention relates to monoclonal antibodies with high ADCC activity, characterised in having glycannic structures with a ratio (fucose content/galactose content) of 0.6 or less on the glycosylation site thereof in the Fc region. The invention also relates to pharmaceutical compositions, containing said monoclonal antibodies with high effector activity.
摘要翻译： 本发明涉及具有高ADCC活性的单克隆抗体，其特征在于具有在Fc区的糖基化位点上具有0.6或更小比例（岩藻糖含量/半乳糖含量）的甘氨酸结构。 本发明还涉及含有具有高效应物活性的所述单克隆抗体的药物组合物。
-
公开(公告)号：US20100323368A1
公开(公告)日：2010-12-23
申请号：US12585900
申请日：2009-09-28
申请人： Christophe de Romeuf , Christine Gaucher , Arnaud Glacet , Frédéric Dhainaut , Dominique Bourel , Nicolas Bihoreau , Emmanuel Nony
发明人： Christophe de Romeuf , Christine Gaucher , Arnaud Glacet , Frédéric Dhainaut , Dominique Bourel , Nicolas Bihoreau , Emmanuel Nony
IPC分类号： G01N33/53
CPC分类号： G01N33/6869 , C07K16/2833 , C07K16/2887 , C07K16/34 , C07K2317/14 , C07K2317/732 , G01N33/5047 , G01N33/6863 , G01N2333/70535
摘要： The invention relates to a method of measuring the activation of an effector cell belonging to the immune system, which may or may not be transformed, using a monoclonal (AcMo) or polyclonal antibody. The invention is characterised in that it consists in: bringing into contact (i) CD16 receptor-expressing cells in a reaction medium in the presence of the antibody and (ii) the antigen of said antibody, and measuring the quantity of at least one cytokine produced by the CD16 receptor-expressing cell. The invention also relates to the selection of an antibody capable of inducing the expression of cytokines and interleukins, such as IFN? or IL2 which are intended for the treatment of autoimmune and inflammatory diseases, cancers and infections by pathogens.
摘要翻译： 本发明涉及一种使用单克隆（AcMo）或多克隆抗体测量属于免疫系统的效应细胞的激活的方法，其可以或可能不被转化。 本发明的特征在于：其在抗体存在下使反应介质中的CD16受体表达细胞接触（i）和（ii）所述抗体的抗原，并测量至少一种细胞因子的量 由CD16受体表达细胞产生。 本发明还涉及能够诱导细胞因子和白介素（例如IFNα）表达的抗体的选择。 或IL2，其用于治疗自身免疫性和炎性疾病，癌症和病原体的感染。
-
公开(公告)号：US07595165B2
公开(公告)日：2009-09-29
申请号：US10527665
申请日：2003-09-15
申请人： Christophe de Romeuf , Christine Gaucher , Arnaud Clacet , Frédéric Dhainaut , Dominique Bourel , Nicolas Bihoreau , Emmanuel Nony
发明人： Christophe de Romeuf , Christine Gaucher , Arnaud Clacet , Frédéric Dhainaut , Dominique Bourel , Nicolas Bihoreau , Emmanuel Nony
IPC分类号： G01N33/53 , G01N33/567 , C12N5/00 , C07K17/00
CPC分类号： G01N33/6869 , C07K16/2833 , C07K16/2887 , C07K16/34 , C07K2317/14 , C07K2317/732 , G01N33/5047 , G01N33/6863 , G01N2333/70535
摘要： The invention relates to a method of measuring the activation of an effector cell belonging to the immune system, which may or may not be transformed, using a monoclonal (AcMo) or polyclonal antibody. The invention is characterised in that it consists in: bringing into contact (i) CD16 receptor-expressing cells in a reaction medium in the presence of the antibody and (ii) the antigen of said antibody, and measuring the quantity of at least one cytokine produced by the CD16 receptor-expressing cell. The invention also relates to the selection of an antibody capable of inducing the expression of cytokines and interleukins, such as IFN? or IL2 which are intended for the treatment of autoimmune and inflammatory diseases, cancers and infections by pathogens.
摘要翻译： 本发明涉及一种使用单克隆（AcMo）或多克隆抗体测量属于免疫系统的效应细胞的激活的方法，其可以或可能不被转化。 本发明的特征在于：其在抗体存在下使反应介质中的CD16受体表达细胞接触（i）和（ii）所述抗体的抗原，并测量至少一种细胞因子的量 由CD16受体表达细胞产生。 本发明还涉及能够诱导细胞因子和白介素（例如IFNα）表达的抗体的选择。 或IL2，其用于治疗自身免疫性和炎性疾病，癌症和病原体的感染。
-
8.发明申请Treatment of pathologies which escape the immune response, using optimised antibodies 审中-公开使用优化的抗体治疗逃避免疫应答的病理学公开(公告)号：US20050271652A1
公开(公告)日：2005-12-08
申请号：US10527666
申请日：2003-09-15
IPC分类号： A61K39/395 , A61P7/00 , A61P31/00 , A61P33/00 , A61P35/00 , C07K16/00 , C07K16/28 , C07K16/34
CPC分类号： C07K16/2833 , C07K16/2896 , C07K16/34 , C07K2317/732
摘要： The invention relates to the use of optimised human or humanised chimeric monoclonal antibodies which are produced cell lines, said antibodies having a strong affinity for receptor CD16 of the effector cells of the immune system and being able to induce the secretion of cytokines and interleukins, in particular 1′ IFN? or 1′ IL2, for the treatment of pathologies for which the target cells only express a low antigenic density and in which the effector cells can only be recruited in small quantities.
摘要翻译： 本发明涉及使用产生细胞系的优化的人或人源化嵌合单克隆抗体，所述抗体对免疫系统的效应细胞的受体CD16具有强亲和力，并能够诱导细胞因子和白细胞介素的分泌， 特别是1' 或1'IL2，用于治疗靶细胞仅表达低抗原密度并且其中仅能够少量招募效应细胞的病理学。
-
公开(公告)号：US20110059072A1
公开(公告)日：2011-03-10
申请号：US12502915
申请日：2009-07-14
申请人： Roland Beliard , Dominique Bourel , Arnaud Glacet , Christophe de Romeuf , Nicolas Bihoreau , Emmanuel Nony
发明人： Roland Beliard , Dominique Bourel , Arnaud Glacet , Christophe de Romeuf , Nicolas Bihoreau , Emmanuel Nony
IPC分类号： A61K39/395 , A61P35/00
CPC分类号： C07K16/34 , A61K2039/505 , C07K2317/14 , C07K2317/21 , C07K2317/41 , C07K2317/52 , C07K2317/732
摘要： The invention concerns a method for obtaining and selecting monoclonal antibodies by an ADDC-type test, said antibodies capable of activating type III Fcγ receptors and having a particular glycan structure. The inventive anti-D antibodies can be used for preventing Rhesus isoimmunisation in Rh negative persons, in particular for haemolytic disease in a new-born baby or for uses such as idiopathic thrombocytopenic purpura (ITP).
摘要翻译： 本发明涉及通过ADDC型测试获得和选择单克隆抗体的方法，所述抗体能够激活III型Fcγ受体并具有特定的聚糖结构。 本发明的抗D抗体可用于预防Rh阴性人中的恒河猴异免疫，特别是新生婴儿中的溶血性疾病或特发性血小板减少性紫癜（ITP）等用途。
-
公开(公告)号：US08357370B2
公开(公告)日：2013-01-22
申请号：US13443532
申请日：2012-04-10
申请人： Roland Beliard , Dominique Bourel , Arnaud Glacet , Christophe de Romeuf , Nicolas Bihoreau , Emmanuel Nony
发明人： Roland Beliard , Dominique Bourel , Arnaud Glacet , Christophe de Romeuf , Nicolas Bihoreau , Emmanuel Nony
IPC分类号： A61K39/395
CPC分类号： C07K16/34 , A61K2039/505 , C07K2317/14 , C07K2317/21 , C07K2317/41 , C07K2317/52 , C07K2317/732
摘要： The invention concerns a method for obtaining and selecting monoclonal antibodies by an ADDC-type test, said antibodies capable of activating type III Fcγ receptors and having a particular glycan structure. The inventive anti-D antibodies can be used for preventing Rhesus isoimmunisation in Rh negative persons, in particular for haemolytic disease in a new-born baby or for uses such as idiopathic thrombocytopenic purpura (ITP).
摘要翻译： 本发明涉及通过ADDC型测试获得和选择单克隆抗体的方法，所述抗体能够激活III型Fcγ受体并具有特定的聚糖结构。 本发明的抗D抗体可用于预防Rh阴性人中的恒河猴异免疫，特别是新生婴儿中的溶血性疾病或特发性血小板减少性紫癜（ITP）等用途。
-
-
-
-
-
-
-
-
-
搜索结果
32 条记录 (耗时 0.026 秒)
